Evolving therapeutic paradigms for multiple myeloma: Back to the future

Benjamin M. Cherry, Neha Korde, Mary Kwok, Mark Roschewski, Ola Landgren

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

Multiple myeloma (MM) is an ancient disease, but until the alkylating agent melphalan was found to have anti-myeloma properties in the 1950s there was virtually no effective therapy. By the late 1960s, extended dosing with melphalan and prednisone tripled survival from diagnosis and became the standard of care for newly diagnosed MM. "Maintenance therapy" to prolong survival through sustained disease control following induction chemotherapy was sought by 1970, but early strategies were ineffective and toxic. Subsequent applications of high-dose therapy (HDT)/autologous stem cell transplant (ASCT) changed the treatment paradigm for MM from extended dosing to an intensive strategy designed to eradicate the malignant cells in a single course of treatment. Although HDT-ASCT resulted in prolonged duration of remission and improved survival, the vast majority of patients still relapsed. Interferon (IFN) and glucocorticoid maintenance therapies demonstrated marginal improvements in outcomes but significant adverse effects. Novel agents introduced over the last decade have prolonged survival when given for maintenance following HDT-ASCT, but have also challenged the HDT-ASCT paradigm by achieving comparable remission rates when used alone as extended frontline therapy. This article reviews the evolution of therapeutic strategies for MM and discusses future questions facing MM investigators.

Original languageEnglish (US)
Pages (from-to)451-463
Number of pages13
JournalLeukemia and Lymphoma
Volume54
Issue number3
DOIs
StatePublished - Mar 2013
Externally publishedYes

Keywords

  • Extended dosing
  • Lenalidomide
  • Maintenance
  • Multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Evolving therapeutic paradigms for multiple myeloma: Back to the future'. Together they form a unique fingerprint.

Cite this